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BACKGROUND: The aim of this work was to improve the knowledge of the role of histamine in breast cancer by assessing the
therapeutic efficacy of histamine and histamine H4 receptor (H4R) ligands in a triple-negative breast cancer (TNBC) model
developed in immunocompetent hosts. By using publicly available genomic data, we further investigated whether histidine
decarboxylase (HDC) could be a potential biomarker.
METHODS: Tumours of 4T1 TNBC cells were orthotopically established in BALB/c mice. Treatments employed (mg kg−1): histamine
(1 and 5), JNJ28610244 (H4R agonist, 1 and 5) and JNJ7777120 (H4R antagonist, 10).
RESULTS: Increased HDC gene expression is associated with better relapse-free and overall survival in breast cancer patients.
Histamine treatment (5 mg kg−1) of 4T1 tumour-bearing mice reduced tumour growth and increased apoptosis. Although no
immunomodulatory effects were observed in wild-type mice, significant correlations between tumour weight and cytotoxic
lymphocyte infiltration were detected in H4R knockout mice. H4R agonist or antagonist differentially modulated tumour growth
and immunity in 4T1 tumour-bearing mice.
CONCLUSIONS: Histamine plays a complex role and stands out as a promising drug for TNBC treatment, which deserves to be
tested in clinical settings. HDC expression level is associated with clinicopathological characteristics, suggesting a prognostic value
in breast cancer.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0636-x
BACKGROUND
Breast cancer is the most commonly diagnosed neoplasia and the
leading cause of cancer-related mortality in women worldwide.1 It
is a heterogeneous disease, showing different histological types,
molecular profiles and clinical responses to therapy.2
Triple-negative breast cancer (TNBC) accounts for the 10–20%
of breast carcinomas and is characterised by the lack of expression
of the oestrogen receptor, progesterone receptor and human
epidermal growth factor 2 receptor proteins, and its poor
prognosis is associated with a lower rate of relapse-free survival
and overall survival. TNBC is the most aggressive subtype of breast
cancer with a high proliferative and metastatic potential. As no
targeted therapy is available, toxic chemotherapy remains as the
only established standard treatment.3,4 Therefore, the identifica-
tion of novel molecular targets for TNBC treatment is urgently
needed.
Numerous evidence from both human and murine studies
support the key role of the immune system not only in cancer
development and progression but also in the response to
antitumour treatments.5–7 In this regard, a positive correlation
between the presence of tumour-infiltrating lymphocytes (TILs)
and patients’ survival was demonstrated in different types of
tumours, including breast cancer.8 In TNBC, in particular, immune
escape is principally associated with an immunosuppressive
tumour microenvironment.9 Therefore, the search for therapeutic
strategies that evade immunosuppression, potentiating antitu-
mour immunity and favouring the reduction of metastasis is of
utmost importance to improve the survival and quality of life of
cancer patients.8
Histamine is a biogenic amine with numerous immunomodu-
latory roles, including modulation of acute and chronic inflam-
matory and immediate hypersensitivity responses.10–12 Histamine
effects are mediated by the activation of four different receptor
subtypes H1, H2, H3 and H4 receptors (H1R, H2R, H3R and H4R),
which belong to the family of seven transmembrane domain G-
protein-coupled receptors.11,12
Besides the well-documented immune cell responses of
histamine, which are mediated by H1R and H2R, new physio-
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and pathophysiological roles of the latest discovered H4R have
been reported over the last decade.12–16 The H4R is mainly
expressed in cells of the immune system, such as mast cells,
basophils, eosinophils, monocytes, dendritic cells, T lymphocytes
and natural killer (NK) cells,12,15 and its functional expression is
demonstrated in different types of tumours.11,17–20 H4R was found
in human breast cancer tissues and cell lines. The in vivo
administration of histamine or H4R agonists diminished the
tumour growth of human TNBC developed in immune-deficient
nude mice with MDA-MB-231 cells.21,22 Importantly, we have
recently demonstrated a novel role of H4R in the antitumour
immunity of breast cancer,23 which could affect the clinical
therapeutic outcomes of histamine-related pharmacological
compounds.
In addition, many studies have described the expression and
activity of the histamine-synthesising enzyme histidine decarbox-
ylase (HDC) in breast cancer patients, but the results are somehow
controversial, while its prognostic relevance in breast cancer is still
not known.20
In the context of the complexity of cancer, effective therapeu-
tics should target the different molecular participants encom-
passed in a tumour, as well as their specific interactions with the
tumour microenvironment. In this regard, histamine, a pleiotropic
compound, could be an attractive cancer therapeutic agent.
Histamine dihydrochloride administration has been approved in
Europe for the treatment of acute myeloid leukaemia, used in
combination with the immunotherapeutic agent IL-2, a fact that
encourages the study of this biogenic amine as an adjuvant to
therapeutic approaches for other cancers.24,25
The aim of this work was to improve the knowledge about the
role of histamine in breast cancer. By using publicly available
genomic data, we first investigated whether HDC could be a
potential biomarker, which could correlate with breast cancer
prognosis in terms of survival. We further assessed the therapeutic
efficacy of histamine and H4R ligands in a preclinical TNBC model
developed in immunocompetent host, in which the influence of
the immune system in the response to therapeutics could be
evaluated.
The results show that histamine plays a complex role and stands
out as a promising drug for TNBC treatment, which deserves to be
tested in clinical settings.
METHODS
Chemicals
Histamine (Sigma Chemical Co., Missouri, USA); H4R agonist:
VUF8430 (VUF) (Tocris Bioscience, Ellisville, Missouri, USA);
JNJ28610244 (JNJ28) (Janssen Research & Development, San
Diego, USA). H4R antagonist: JNJ7777120 (JNJ77) (Janssen
Research & Development).
Cell culture
The 4T1 tumour cell line (ATCC CRL-2539) was cultured and
maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% (v/v) FBS, 0.3 g L−1 glutamine, 100 µg
ml−1 streptomycin and 100 Uml−1 penicillin (all from Gibco BRL,
Grand Island, NY, USA).23 Cells were maintained at 37 °C in a
humidified atmosphere containing 5% CO2.
Cell proliferation assays
For clonogenic assay, cells were left untreated or were treated
with 0.01–50 μmol L−1 of histamine or JNJ28 and/or 10 μmol L−1
JNJ77 for 5–7 days. We proceeded as previously reported.26 The
clonogenic proliferation was evaluated by counting the colonies
containing 50 or more cells and was expressed as a percentage of
the untreated wells.
For the quantification of cellular DNA synthesis, cells were
seeded into 12-well plates (2.5 × 104 cells/well), and treated with
10 μmol L−1 of histamine, JNJ28 or VUF8430 for 48 h. After that, 5-
bromo-2′-deoxyuridine (BrdU, 30 mmol L−1, Sigma) was added
into culture medium for 2 h. The incorporation of BrdU to
proliferating cells was evaluated as previously described.26 The
percentage of fluorescent cells was determined by using an
Olympus BX50 microscope.
Cell viability was measured with the fluorometric resazurin
reduction method (CellTiter-Blue; Promega, Madison, WI, USA).
Briefly, 5 × 105 cells/mL were seeded at a final volume of 0.1 mL in
96-well flat-bottom microtiter plates and were treated or not for
48 h with 10 μmol L−1 of histamine or JNJ28. Fluorescence was
determined in a BMG Labtech NOVOstar MicroPlate Reader.
Apoptosis determinations
Cells were seeded into 12-well plates (2.5 × 104 cells/well), and
treated with 10 μmol L−1 of histamine, JNJ28 or VUF8430 for 48 h.
Apoptotic cells were determined by TdT-mediated UTP-biotin Nick
End labelling (TUNEL) (Millipore, CA, USA) assay and by staining
with Annexin-V FITC (BD Biosciences, San José, CA, USA) by using
flow cytometry, both according to the manufacturer’s instructions
and previously reported.19,21
The cell-permeant, cationic, red-orange fluorescent dye tetra-
methylrhodamine ethyl ester (TMRE) (Molecular Probes, Life
Technologies Corporation, Carlsbad, CA, USA), which is rapidly
sequestered by active mitochondria, was used to evaluate the
mitochondrial transmembrane potential. Since dead cells become
completely depolarised, we analysed live-gated cells to detect the
decrease in mitochondrial transmembrane potential, which is
associated with apoptosis. Cells were incubated at 37 °C for 30 min
in the presence of 40 nmol L−1 TMRE. They were then harvested
after washing with PBS, and analysed by flow cytometry (BD
Accuri C6, BDB). The mean fluorescence of untreated cells was set
at 100%. CCCP (carbonyl cyanide m-chlorophenyl hydrazone), a
mitochondrial oxidative phosphorylation uncoupler, was used as a
positive control at a concentration of 20 μmol L−1 during 30min.
Breast cancer model in BALB/c mice
Female H4R knockout (H4R−/−) mice were generated as previously
described,27 and were provided by Janssen Research & Develop-
ment, LLC (La Jolla, CA, USA) and back crossed to BALB/c
background. These animals and the corresponding female wild-
type (WT) mice (BALB/c) were bred and kept in ventilated cages at
our animal health care facility at 22–24 °C and 50–60% humidity
on a 12-h light/dark cycle with food and water available ad
libitum.23 Animals with an age of 6–8 weeks and an average
weight of 20–25 g were used.23 All animal protocols were in
accordance with recommendations from the National Institute of
Health Guide for the Care and Use of Laboratory Animals (NIH
Publications No. 8023) and the Guidelines for the welfare and use
of animals in cancer research.23 All procedures were reviewed and
approved by the Institutional Committee for the Care and Use of
Laboratory Animals, BIOMED, and are in accordance with the
ARRIVE guidelines for reporting experiments involving animals.
To generate solid tumours, 6–8-week-old mice were inoculated
orthotopically in the abdominal mammary gland with 1 × 105
syngeneic 4T1 cells in serum-free PBS, as described.23,28 Tumour
length and width were measured every 2 days by using callipers,
and tumour volume was calculated as V= π/6 × length × width2.23
When tumours became palpable, mice were randomly assigned to
the control group (saline treated) or were daily treated (morning)
with subcutaneous (s.c.) injections of histamine (1 mg kg−1 b.w.
or 5 mg kg−1 b.w. diluted in saline), JNJ28 (1 mg kg−1 b.w. or
5 mg kg−1 b.w., resuspended in 0.1 N HCl, neutralised with 4 N
NaOH and diluted with saline) or JNJ77 (10 mg kg−1 b.w., diluted
in saline) for 15 days. The administration was performed in the
animal health care facility on the dorsal flank at concentrations
according to previous studies in TNBC and melanoma models
developed in immunodeficient mice.19–21 The method consists of
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tenting the skin between the shoulder blades and inserting the
needle bevel up in the pocket created. Mice were then killed by
cervical dislocation, and tissues were removed and weighted.
To evaluate the combined effect of irradiation and histamine,
the tumours from control or histamine- (1 mg kg−1 b.w.) treated
mice were irradiated with a daily dose of 2 Gy for 3 consecutive
days as previously described in detail.29 Briefly, 1 day after
treatment began, animals were irradiated with a 2-Gy dose
per day for 3 consecutive days. Mice were anaesthetised with an
intraperitoneal injection of a combination of xylazine (10 mg kg−1)
and ketamine (100 mg kg−1) and fixed on an acryl plate. Tumours
were locally irradiated with a 60Co γ-radiation source (Teradi 800,
at Hospital Municipal de Oncologia “Marie Curie”, Buenos Aires),
while other body parts were protected with lead blocks.
Histochemistry and immunostaining
Tumours and tissues were excised, fixed in 4% (v/v) formaldehyde
in PBS (formalin), paraffin-embedded and sliced into 4-μm thick
sections to evaluate the histological characteristics on
haematoxylin–eosin (H&E)-stained specimens (Biopur diagnostic,
Buenos Aires, Argentina). The mitotic index, intratumoural
vascularity and the number of lung metastasis were evaluated.
Immunohistochemistry was performed with primary rabbit
antihistamine (1:100), rabbit anti-HDC (1:100) and mouse anti-
proliferating cell nuclear antigen (PCNA, 1:100) antibodies (see
Supplementary Table 1 for more information). The fragmented
DNA was detected by using ApoptagTM plus peroxidase in situ
apoptosis Detection Kit (Millipore) according to the manufacturer’s
instructions.
All these procedures were previously described in detail.19,21
Visualisation of samples was performed with an optical
microscope Axiolab Carl Zeiss (Germany), and photographs were
taken at ×630 magnification with Canon Power Shot G5 camera
(Japan).
Preparation of single-cell suspensions from lymph nodes, spleens
and tumours
After removal, lymphoid organs were disrupted through a 1-mm
metal mesh. Tumours were minced and digested with 2 mgmL−1
collagenase type I (Gibco) in serum-free DMEM for 30min at 37 °C.
After centrifugation, the red blood cells were lysed, and the
resulting cell suspensions were then filtered through a 40-µm cell
strainer (BDB) and resuspended in PBS.23,28
Flow cytometry for immunophenotyping
Single-cell suspensions obtained from tumours, tumour-draining
lymph nodes (TDLN), non-draining lymph nodes (LN) and spleens
were stained with antibodies against various cell surface markers
by using standard staining methods, as previously described.23,28
The fluorochrome-conjugated antibodies that were used in the
study are shown in Supplementary Table 1. Samples were run on a
BD Accuri C6 flow cytometer (BDB), and data were analysed by
using the BD Accuri C6 software (BDB). The percentage of tumour-
infiltrating lymphocytes (TILs) was determined by forward- and
side-scatter properties of these cells. The percentages of tumour-
infiltrating CD3+, CD4+, CD8+ and CD3−CD49+ cells are indicated
within the gated population of TILs.
FoxP3 staining
Single-cell suspensions, prepared as described above, were used
for intracellular staining. After CD4 and CD25 surface staining, cells
were fixed with Mouse Fixation Buffer (BDB, 51-9006124) and
permeabilised with Mouse FoxP3 Permeabilization Buffer (BDB,
51-9006125), following the manufacturer's instructions. Cells were
then incubated with the FITC-anti-mouse-FoxP3 antibody (BDB-
560408) for 40 min. After washing with PBS, cells were analysed by
flow cytometry as described above.23
Cytokine determination
Conditioned medium was obtained after cutting tumours
into small pieces and incubating equal quantities of tissue in
complete RPMI medium for 48 h. Alternatively, 4T1 cells were
treated with histamine or JNJ28, and conditioned medium was
obtained after 48 h. Mice interferon (IFN)-γ (BDB-558473), tumour
necrosis factor (TNF) (BDB-558480) and interleukin (IL)-10 (BDB-
558300) CBA Flex Sets were used to analyse specific cytokines in a
BD Accuri C6 flow cytometer, following the manufacturer's
instructions. The results were analysed with FCAP Array Software
v3.0 (BDB).23
TCGA and GEO gene expression and survival analysis
UALCAN is an interactive web portal for facilitating tumour
subgroup gene expression and survival analyses (http://ualcan.
path.uab.edu/).30 We used UALCAN analysis to evaluate HRH4 and
HDC gene expression levels based on tumour sample type and
survival in The Cancer Genome Atlas (TCGA) breast cancer
datasets. RNA-seq data obtained from TCGA samples were
analysed by using Firebrowse web resource (http://firebrowse.
org).31
In addition, the web portal Kaplan–Meier plotter (http://kmplot.
com/analysis/)32 was used to investigate the association between
the level of expression of these genes and relapse-free survival
(RFS) and overall survival (OS). This online tool allowed the
evaluation of the Gene Expression Omnibus (GEO) breast cancer
datasets.
Genomic alteration frequency of HDC in breast cancer patients
was performed by using TCGA data and CBioPortal web resource
(http://www.cbioportal.org/).33
GSE62598 microarray dataset from the GEO database was used
to evaluate HDC expression on different sources of 4T1 breast
cancer model (www.ncbi.nlm.nih.gov/geoprofiles).
Statistical analyses
The results are presented as the mean ± standard error of the
mean (SEM) or the median and interquartile range, as indicated.
Student’s t test or nonparametric Mann–Whitney U test were used
for comparisons between two groups. One-way ANOVA followed
by Newman–Keuls multiple comparison test or nonparametric
Kruskal–Wallis test was used for comparisons between more than
two groups. Spearman’s r correlation coefficient and two-tailed
significances were determined when appropriate. All statistical
analyses were performed with GraphPad Prism version 7.00 (CA,
USA). The “n” values represent the number of observations or the
number of animals used.
RESULTS
Association of HDC gene expression with survival outcomes in
breast cancer patients
To shed light on the role of histamine in breast cancer
progression, we first analysed changes in HDC expression levels
between breast cancer and adjacent non-tumour tissues (normal),
by using publicly available transcriptomic data. TCGA database
and UALCAN web portal revealed that primary tumour samples
exhibited reduced levels of HDC when compared with normal
tissue (Fig. 1a). Notably, the level of HDC mRNA expression in
TNBC tissue was lower than in other breast cancer types
(Supplementary Table 2). In addition, the Firebrowse web resource
demonstrated a 0.4-fold change of HDC expression in tumour vs.
normal tissue.
To determine the association between HDC gene expression
and survival rates in breast cancer patients, large-scale human
cancer gene expression independent databases were searched.
Kaplan–Meier curves for overall survival of patients with breast
cancer were obtained according to the low and high expression
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levels of HDC gene. Patients with high mRNA expression for HDC
had significantly better overall survival than those in the low/
medium expression group (Fig. 1b).
In addition, survival analysis from KM plotter, another publicly
available breast cancer microarray database,32 showed a signifi-
cant correlation between high expression levels of HDC and a
better overall survival and relapse-free survival in all breast cancer
patients (Fig. 1c, d). This was also observed in basal-like breast
cancer patients, who have the worst prognosis among all
subtypes and overlap with TNBC patients in this database
(Supplementary Table 2).34
The analysis of the available data from cBioPortal revealed a
frequency of about 3% in HDC alterations in breast cancer,
including amplifications and deep deletions (Fig. 1e).
Expression of HDC in BRCA
based on sample types (TCGA)
Relapse free survival
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Collectively, these findings suggest that the reduced expression
of HDC in breast cancer patients might be involved in cancer
progression and could be associated with the prognosis of the
disease.
Effect of histamine treatment on 4T1 TNBC tumour growth
parameters and antitumour immunity
We next evaluated the effect of histamine treatment in a murine
TNBC experimental model developed with 4T1 cells. From the
GSE62598 dataset of GEO database, we assessed the HDC
expression in 4T1 TNBC. This histamine-synthesising enzyme
seemed to be downregulated in tumour explants and liver-
aggressive explants compared with 4T1 parental cells (Fig. 1f). We
additionally investigated the expression of HDC and intracellular
histamine in 4T1 tumours. The presence of intracellular histamine
and HDC was observed in all samples (Fig. 2i, j). However, the
levels of HDC protein expression were more variable among
specimens (Fig. 2i).
We evaluated the effect of histamine administration in vivo, on
tumours developed in BALB/c mice by orthotopic injection of 4T1
TNBC cells (Fig. 2a). Two different concentrations of histamine (1
and 5mg kg−1) were used, according to previous studies in TNBC
and melanoma models developed in immunodeficient mice.19–21
However, only histamine at 5 mg kg−1 significantly reduced the
tumour volume and weight (0.65 ± 0.06 vs. 0.91 ± 0.06 g, P < 0.05)
(Fig. 2b). Although histamine at 1 mg kg−1 concentration was not
able to decrease tumour growth as a single agent, it significantly
enhanced the therapeutic effect of radiation, by reducing
exponential tumour growth and inducing a significant decrease
in the tumour weight (Fig. 2c).
For further experiments histamine was used at a concentration
of 5 mg kg−1. Histopathological analysis of all tumours demon-
strated the presence of undifferentiated adenocarcinoma cells
with a high grade of nuclear polymorphism (Fig. 2i). In addition, it
showed that tumours from histamine-treated mice presented a
reduced mitotic index (Fig. 2d) and a lower percentage of PCNA-
positive cells (Fig. 2e, i). In addition, histamine significantly
increased the number of apoptotic cells compared with the
untreated animals (Fig. 2g, i). Treatment of 4T1-bearing mice with
histamine reduced the number of intratumoural vessels (Fig. 2f)
and non-significantly decreased the number of microscopic lung
metastases (Fig. 2h, P= 0.0683). In line with the histamine-
induced inhibition of tumour growth, histamine-treated animals
also showed reduced splenomegaly (Fig. 2k). In both experimental
groups, the splenic weight was correlated with tumour weight
(Fig. 2l), as it has been previously described for this TNBC
experimental model.35
In view of the critical role of immunity in the tumour
microenvironment and the pivotal immunomodulatory role of
histamine, the inflammatory tumour infiltrate was next investi-
gated. To this end, TILs were evaluated by FACS according to the
gating strategy depicted in Fig. 3a. A non-significant higher
percentage of TILs was observed in tumours from the histamine-
treated group [median 8.04 (3.79–20.08), n= 15] compared with
the control group [median 5.13 (1.79–8.87), n= 15, P > 0.05,
Mann–Whitney test], and a negative correlation was observed
between TILs and tumour weight only on histamine-treated animals
(Fig. 3b). The analysis of the distribution of the tumour-infiltrating
immune cell subsets within the TIL-gated population was next
performed and showed no significant changes in the percentage of
CD3+, CD4+ or CD8+ T lymphocytes, or NK cells between treated
and untreated animals (Fig. 3c–f). Treg cell population was not
detected in tumours. Since myeloid cells are major components of
tumour microenvironment and are involved in cancer progression,8
they were further investigated. The results showed no significant
differences neither in the percentage of tumour-infiltrating
CD11b+Gr1+ myeloid-derived suppressor cells (MDSC) nor in F4/
80+ macrophages when histamine-treated and untreated mice
were compared (Supplementary Fig. 1). Likewise, histopathological
analysis revealed no changes in intratumoural neutrophils, eval-
uated by their morphological characteristics (Fig. 2j).
The analysis of cytokine production in the conditioned medium
of tumours showed no differences in the levels of TNFα (Fig. 3g).
However, a non-significant increase in IFNγ levels was detected in
the conditioned medium from tumours derived from histamine-
treated mice (Fig. 3h).
The effect of the treatment with histamine (5 mg kg−1) on the
distribution of immune cells in the spleens, non-draining lymph
nodes (LN) and tumour-draining lymph nodes (TDLN) of 4T1
tumour-bearing mice was additionally evaluated. No significant
differences were observed regarding the percentages of CD4+ or
CD8+ T lymphocytes nor NK cells in the spleen or in the lymph
nodes of both animal groups (Supplementary Figs. 2, 3, 4). The
cytotoxic activity of splenic NK cells and CD8+ T cells from spleens,
TDLN and LN was further investigated, but no changes were
detected between the control and histamine-treated group
(Supplementary Figs. 3 and 4). A non-significant reduction of the
percentage of CD4+CD25+FoxP3+ Treg cells was observed in the
spleens and LN of animals treated with histamine (5 mg kg−1)
compared with the control group (Supplementary Fig. 2).
In line with these results, no significant correlations between
tumour weight and cytotoxic lymphocyte infiltration, cytotoxic
T cells (CD8+) and NK cells, were observed in untreated or
histamine-treated tumour-bearing wild-type mice. Surprisingly,
negative correlations between the percentage of tumour-
infiltrating NK cells, CD8+ T lymphocytes or activated CD8+
CD44+ T lymphocytes and tumour weight were detected only in
histamine-treated H4R knockout (KO) mice. In addition, a
significant positive correlation between the ratio of CD4+/CD8+
T cells and tumour weight was observed upon histamine
treatment in H4R-KO mice, further demonstrating the crucial role
of H4R in immunosurveillance (Table 1).
Fig. 1 Analysis of histidine decarboxylase (HDC) expression and its association with clinical characteristics of breast cancer patients. a Boxplot
generated in the UALCAN interactive web resource (http://ualcan.path.uab.edu/), shows relative expression of HDC in transcript per million
units (TPM) in paired normal and primary tumour of breast-invasive carcinoma (BRCA) patients. The samples used for the analysis derived
from the genomic data of The Cancer Genome Atlas (TCGA) (T test). b Kaplan–Meier plot generated in the UALCAN with TCGA data
demonstrates the association of HDC expression levels with patient overall survival. Samples were categorised into two groups: high
expression (red line, with TPM values above the upper quartile), and low/medium expression (blue line, with TPM values below the upper
quartile), and the difference was compared by log-rank test (P < 0.05 was indicated the cutoff value). c, d Kaplan–Meier plots generated in the
portal web Kaplan–Meier Plotter (http://kmplot.com/analysis/) show the association of HDC expression levels with (c) patient relapse-free
survival and (d) patient overall survival. The samples used for the analysis derived from the Gene Expression Omnibus (GEO) and the “Cartes
d’Identité des Tumeurs (CIT)” breast cancer (BRCA) datasets. Red line: patients with expression levels above the median; black line: patients with
expression levels below the median. The two patient cohorts are compared by a Kaplan–Meier survival plot, and the hazard ratio with 95%
confidence intervals and log-rank P-value are calculated. Additional clinical parameters are displayed in Supplementary Table 2. e Genomic
alteration frequencies of HDC in breast cancer patients. The analysis was performed by using CBioPortal database (www.cbioportal.org).
f GSE62598 microarray dataset from the GEO database was used to evaluate HDC expression on different sources of 4T1 breast cancer model
(Mann–Whitney test, P-value compared with 4T1 parental cells)
Study of the antitumour effects and the modulation of immune response by. . .
MB Nicoud et al.
5
Effect of H4R ligands on 4T1 TNBC tumour growth parameters and
antitumour immunity
To improve our knowledge on the role of H4R in histamine-
mediated responses, the effect of an H4R agonist (JNJ28) and an
H4R antagonist (JNJ77) was evaluated in vivo by employing
the 4T1 breast cancer model. Only 1 mg kg−1 of JNJ28, but not
5 mg kg−1 (data not shown), exhibited an antitumour effect,
significantly reducing the tumour volume and its weight at the
end of the experiment, together with a decrease in spleen weight
(Fig. 4a, b). However, at this concentration, no significant
differences were observed in the number of TILs or immune cell
subset distribution in tumours of JNJ28-treated mice compared
with untreated ones (Fig. 4c–f). The evaluation of the immune cell
subsets in secondary lymphoid organs, however, indicated that
JNJ28 administration increased the percentage of CD4+ T cells in
TDLN compared with untreated animals (Fig. 4g).
On the other hand, dissimilar effects were observed upon
administration of the H4R antagonist JNJ77, at a concentration
BALB/c female mice
6 – 8 week old
Injection of 1×105 4T1 cells
in abdominal mammary 
gland
Treatments: Saline (control),
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routinely employed. JNJ77 treatment non-significantly reduced
tumour weight and spleen weight, while it significantly decreased
the percentage of tumour-infiltrating CD4+ T lymphocytes and
further reduced the percentage of Tregs in TDLN (Fig. 4a, b, d, h).
None of the compounds significantly altered the percentage CD8+
T cells or NK cells within the tumour infiltrate or TDLN (Fig. 4e, f, i).
Interestingly, only in JNJ77-treated mice, the percentage of
CD8+ T cells in TDLN negatively correlated with tumour weight,
and the intratumoural ratio CD4+/CD8+ T cells positively
correlated with tumour weight (Fig. 4j, k). No important adverse
events were observed upon treatment with any compound.
Direct antiproliferative and proapoptotic effects of H4R agonists
on 4T1 cells
With the aim of trying to discern the contribution of a direct action
of the compounds on tumour cells, we performed in vitro studies
to evaluate the effect of H4R agonists on the proliferative and
apoptotic responses of 4T1 cells, which are known to express H4R
at the mRNA and protein levels.23 The results demonstrated that
histamine regulated the clonogenic proliferation of 4T1 cells in a
dose-dependent manner, exhibiting an IC50 of 0.99 µmol L
−1
(Fig. 5a). H4R agonist JNJ28 showed an IC50 of 1.68 µmol L
−1
(Fig. 5a). The antiproliferative effects of histamine and JNJ28 were
blocked by the addition of the specific H4R antagonist JNJ77 at
the concentration of 10 µmol L−1 (Fig. 5b).
As expected, cell viability was significantly decreased in cells
that were treated with histamine (10 µmol L−1) and JNJ28
(10 µmol L−1), as it was evidenced by lower mean fluorescence
intensities than untreated cells in the Cell Titer Blue Assay (Fig. 5c).
The antiproliferative role of H4R was also confirmed with the BrdU
assay in cells treated with histamine, JNJ28 or VUF8430, another
H4R agonist (Fig. 5d). In addition, the treatment of 4T1 cells with
histamine and both JNJ28 and VUF8430 increased the percentage
of apoptotic cells, evaluated by TUNEL assay and flow cytometric
analysis of Annexin-V staining (Fig. 5e, f). Accordingly, treatment
with histamine and JNJ28 reduced mitochondrial transmembrane
potential evaluated by TMRE staining (Fig. 5g). In agreement with
these results, high HRH4 gene expression in breast tumours is
associated with a better patient relapse-free survival (Supplemen-
tary Table 2).
Finally, we evaluated if H4R agonists can regulate the pattern of
cytokine secretion by 4T1 cells. The conditioned media obtained
after 48 h of culture showed undetectable levels of IFNγ in
untreated as well as in histamine- or JNJ28-treated cells. Likewise,
TNFα secretion levels were similar in all experimental conditions.
However, a significant increase in IL-10 levels was detected only in
JNJ28-treated 4T1 cells (Fig. 5h).
DISCUSSION
The triple-negative tumours are undoubtedly one of the most
relevant subgroups of breast cancer given their lack of targeted
therapies, their aggressive clinical behaviour and poor prog-
nosis.4,36,37 Identifying novel potential biomarkers for early
diagnosis, prognostic determination or targeted therapy are of
utmost importance to improve TNBC patient outcomes. In this
sense, TCGA and other publicly available databases, such as GEO,
produce a rich and invaluable genomic data generation, which
notably contributes to accelerate the understanding of the
molecular basis of cancer and to improve drug development
and treatment strategies.
In the present work, we first analysed the expression of the
histamine-synthesising enzyme HDC in human breast cancer
tissues. Genomic data from TCGA show that HDC is down-
regulated in breast cancer in comparison with normal tissue.
Samples from the most aggressive cancer subtypes, such as TNBC,
exhibited the lowest HDC gene expression levels. Further
supporting the relevance of histamine in cancer progression, the
results demonstrated that higher HDC expression predicted longer
overall survival. In addition, higher expression of HDC was
significantly associated with improved disease-free survival in all
breast cancer patients as well as in TNBC patients, suggesting that
histamine may reduce or delay metastatic breast cancer. In this
line, elevated HDC gene expression was associated with improved
survival outcomes in colorectal cancer patients.38 We could also
describe genomic alterations of HDC in breast cancer samples. In
this regard, a study in the Chinese Han population showed that
polymorphisms of HDC gene were associated with breast cancer,
further highlighting the clinical relevance of HDC in this disease.39
Thus, our results suggest that high HDC expression might
predict a better clinical outcome, reducing the risk of cancer
relapse and might be a novel prognostic marker for breast cancer
progression. Further immunohistochemical studies in a large
number of tumour samples are needed to validate the use of HDC
as a biomarker, which could complement routine histopathologi-
cal analysis. Considering that the HDC activity is regulated at
different levels, the presence of HDC proteolytic variants and other
post-translational modifications should be considered in the
analysis.12
Preclinical research from different groups has shown the
therapeutic efficacy of histamine and specific H4R agonists in
different experimental cancer models. But these studies have
been mainly performed in immunodeficient hosts, in which the
effect of the immune system in response to therapeutics could
not be contemplated. Considering the key role of histamine and
H4R in immunomodulation, it is necessary to corroborate the
Fig. 2 Tumour growth parameters of 4T1 tumour-bearing mice treated with histamine. a Experimental design. BALB/c mice were
orthotopically inoculated with 4T1 cells and 2 weeks later were treated or not with 1 or 5mg kg−1 of histamine. b The means ± SEM for the
ratio between treated and untreated mice for tumour volume and weight at the end of the experimental period are shown (T test, *P < 0.05
with respect to untreated mice). c Effect of ionising radiation treatment (three doses of 2 Gy) on untreated and 1mg kg−1 histamine-treated
mice bearing 4T1 tumours. Tumour growth curves show the relative tumour volume for irradiated control and histamine-treated mice. Inset:
Tumour weight at the end of the experimental period, relative to control non-irradiated group (T test, *P < 0.05). d–g Tumour sections from
control (n= 10) and 5mg kg−1 histamine-treated mice (n= 10) were stained with H&E or immunostained with specific antibodies. The box
plots represent the median and interquartile range for each experimental group (Mann–Whitney test, *P < 0.05, **P < 0.01). d Mitotic index:
number of cells with visible chromosomes at ×400 magnification in 5 random fields. e Percentage of PCNA-positive cells per field at ×400
magnification in 10 random fields. f # of vessels: Number of intratumoural vessels at ×200 magnification in 10 random fields (hotspots).
g Number of TUNEL-positive cells per field at ×400 magnification in 10 random fields. h Number of microscopic metastatic foci covering lungs
at ×400 magnification in 10 random fields. Box plots represent the median and interquartile range for each experimental group
(Mann–Whitney test). i Representative images for H&E staining, TUNEL-positive cells and PCNA, histamine and HDC-positive immunostaining
of paraffin-embedded 4T1 tumours (×630 and ×400 original magnification, scale bar= 20 µm). j Tumour sections from control and 5mg kg−1
histamine-treated mice were stained with specific antibodies against histamine (HA) or histidine decarboxylase (HDC). The results
representing the means ± SEM of the percentage of positive cells per field at ×400 magnification in 10 random fields are shown (t test).
# number of polymorphonuclear neutrophils (PMN), granulocytes with visible segmented nucleus at ×400 magnification in 5 random fields is
depicted (t test). k Spleen weight of control and histamine-treated 4T1 tumour-bearing mice (Mann–Whitney test, *P < 0.05 vs. control).
l Spearman correlation of spleen weight vs. tumour weight for control mice (r: 0.6508, **P= 0.0019; n= 20) and mice treated with histamine
(r: 0.7860, **P < 0.0001; n= 20)
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therapeutic benefit globally, by considering the role of immune
response in the outcome.40
Given the relationship between the histamine-forming enzyme
and the patient’s prognosis, the effect of histamine systemic
treatment on tumour growth and in the immune tumour
microenvironment as a whole was explored in a TNBC syngeneic
model developed in immunocompetent mice. The 4T1 tumour
model resembles human TNBC as it leads to metastasis formation.
It is commonly used for the preclinical evaluation of anticancer
therapies on tumour development and the immune system.28,41
Histamine treatment leading to a dose-dependent effect, was
the highest concentration that has been employed that resulted
to be the therapeutically effective one. Histamine administration
significantly reduced 4T1 tumour size and weight. This effect was
associated with a reduction in the proliferative potential of
tumours and an increase in the apoptotic cell death, together with
a higher infiltration of lymphocytes. In line with these results, we
have previously demonstrated similar effects in a human TNBC
model developed in nude mice in which histamine administration
at 5 mg kg−1 significantly increased the median survival and
tumour apoptosis, while it reduced tumour cell proliferation.21 In
both murine and human TNBC models, histamine reduced the
neovascularisation of the tumour microenvironment. The admin-
istration of histamine also diminished angiogenesis in a human
model of melanoma.19 All 4T1 tumours expressed similar levels of
HDC and exhibited intracellular histamine.
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Fig. 3 Distribution of tumour-infiltrating immune cell subsets in control and histamine-treated mice. Mice bearing 4T1 tumours were treated
with saline (control) or histamine (5 mg kg−1). a Gating scheme for the flow cytometric analysis of tumour-infiltrating lymphocytes (TILs).
Representative data of single-cell suspensions from enzymatically dissociated tumours, labelled with antibodies according to procedures
described in the “Methods” section. Numbers represent the percentage of cells in the respective gate. b The percentage of TILs (% TILs),
determined by flow cytometric analysis of forward vs. side scatter, was correlated with tumour weight for each experimental group. Spearman
correlation for control mice (P > 0.05; n= 15) and mice treated with histamine (correlation coefficient, r: –0.4821, *P < 0.05; n= 15). c–f Tumour
cell suspensions were labelled with specific antibodies, and the percentage of each subset was determined within the TIL-gated population:
c CD3-FITC: T lymphocyte marker (n= 20 control; n= 21 histamine), d CD4-FITC: T helper lymphocyte marker (n= 20 control; n= 21
histamine), e CD8-PE: T cytotoxic lymphocyte marker (n= 20 control; n= 21 histamine), f CD49-PE and CD3-FITC: NK markers (n= 14 control;
n= 14 histamine). g, h Cytokine concentrations in tumour-conditioned medium (n= 12 control; n= 10 histamine). The box plots represent
the median and interquartile range for each experimental group (Mann–Whitney test)
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Histamine being a pleiotropic mediator of inflammatory
responses and a regulator of immune cell functions,12 we further
evaluated the effect of histamine treatment on immune cell
subset distribution. The nature of the developed immune
responses and TILs determines the outcome of antitumour
immunity.42,43 The infiltrating cytotoxic cells, mainly cytotoxic
CD8+ T lymphocytes and NK cells, are ultimately responsible for
killing the cancer cells and controlling the tumour growth. Thus,
the presence of immunosuppressive cells, such as Tregs and
MDSC, is usually associated with worse prognosis.5,44 Unexpect-
edly, the therapeutic concentration of histamine neither modified
the distribution of immune cell subsets nor significantly altered
the activity of CD8+ T lymphocytes and NK cells in 4T1 tumours. In
agreement with previous studies, CD11b+Gr+ MDSC and F4/80+
macrophages were the predominant 4T1 tumour-infiltrating
immune cells,45 but no differences were observed upon histamine
treatment in this myeloid linage cell infiltration.
Histamine treatment non-significantly increased IFNγ produc-
tion in tumours, while no changes were observed in other
important cytokines related to cancer progression, such as
TNFα.46,47 IFNγ is involved in the promotion of hosts’ antitumour
immunity and in the cancer elimination (immunosurveillance)
process, considering its antiproliferative and proapoptotic
effects.5,6,48 In vitro, 4T1 cells produced no detectable levels of
this cytokine (data not shown). Although CD8+ T cells and NK cells
are good candidates for being the intratumoural source of this
cytokine, other immune cells, including B lymphocytes, macro-
phages, dendritic cells and granulocytes,45 could be responsible
for this response.
In agreement with the present results, in a murine lymphoma
model developed with EL-4 cells, histamine treatment reduced
tumour growth while it induced intratumoural accumulation of
maturated dendritic cells.49 In addition, enhanced inflammation
and higher tumour burden at mucosal sites (intestine and skin)
were shown in models of chemically induced carcinogenesis
developed in HDC knockout mice compared with wild-type
animals. These effects were reverted by histamine administra-
tion.50 In this line, the histamine-producing probiotic hdc+
Lactobacillus reuteri decreased the number and size of colon
tumours in HDC KO mice and reduced the gene expression of
proinflammatory cancer-associated cytokines, indicating that
histamine can suppress colorectal tumorigenesis and the severity
of inflammation-associated colon cancer.38 On the other hand,
endogenous histamine contributed to the tumour growth in a
model of breast cancer developed in HDC knockout mice by
suppressing the antitumour immunity.51
Therefore, different histamine levels and altered histamine
metabolism at the tumour site, distinct tumour microenviron-
ments and characteristics and the differential expression of
histamine receptors may determine the outcome of the disease.
It is worth noting that histamine was able to potentiate the
radiation therapeutic effect even at a lower concentration (1 mg
kg−1), suggesting that it could be an attractive agent to be used
also in combination therapies. In this regard, histamine is being
administered as an adjuvant to immunotherapy with IL-2 for the
treatment of patients with metastatic melanoma and acute
myeloid leukaemia, demonstrating clinical benefits.24,52
Considering that 4T1 cells express H4R, here we show evidence
for a direct cytotoxic effect of histamine in vitro through tumour
cell-intrinsic mechanisms involving activation of H4R, which could
contribute to the antitumour and proapoptotic effects described
above with less contribution of immune-mediated effects.
Nevertheless, we cannot discard a histamine-induced modula-
tion of the immune cell subset distribution during tumour
development. However, the effect of histamine on immunocom-
petent cells could be the result of the histamine concentration
reached locally and the affinity constant of the different histamine
receptors expressed in the cells that results in the activation
of receptors with distinct biologic activities. In accordance
with this hypothesis, we have recently demonstrated the
involvement of H4R in the tumour immunity in 4T1 breast cancer,
showing immunosuppressive effects. Thus, endogenous histamine
in H4R- deficient mice produced a reduction of the tumour
size and decreased percentages of CD4+ T cells and Tregs
(CD4+CD25+FoxP3+) in TDLN compared with wild-type mice.23 To
further reinforce the important role of H4R in immunosurveillance,
the present findings show negative correlations between the
tumour-infiltrating cytotoxic subsets, CD8+ T lymphocytes and NK
cells, and the tumour weight, which were only observed in
histamine-treated H4R-KO mice.
To keep deciphering the role of H4R in breast cancer, in the
present work, we investigated the effect of the systemic
administration of the H4R agonist JNJ28 and the H4R antagonist
JNJ77 in the same TNBC model developed in wild-type mice.
It is important to point out that the concentration of JNJ28 to a
large extent determined the outcome of its therapeutic and
immunomodulatory effects in vivo. The lowest concentration
(1 mg kg−1) of JNJ28 slightly, but significantly, reduced tumour
size and increased the percentage of CD4+ T cells in TDLN.
In contrast, a higher concentration (5 mg kg−1) of this agonist
induced no changes in tumour growth (data not shown) probably
because of an immunosuppressive effect on the tumour micro-
environment. We have previously shown that JNJ28 (5 mg kg−1)
increased IL-10 and decreased IFNγ levels in 4T1 tumours, this was
accompanied by an increase in the percentage of Tregs in TDLN.23
In agreement with these results, the treatment with JNJ77 reduced
the percentage of tumour-infiltrating CD4+ T cells and Tregs in
TDLN, similar to the response observed in H4R-KO mice.
Taken together, these results suggest an immunosuppressive
effect of H4R in immune cells. This could partially explain the
effects observed when 4T1 cells were treated with the highest
concentration of H4R agonist, which may in the balance prevail
over the direct antiproliferative effect on tumour cells, and thus it
may be a determinant for the non-effective therapeutic outcome.
On the other hand, in both in vitro studies as well as in vivo
studies performed in immunodeficient hosts, where the role of the
Table 1. Correlation coefficient (r) value of tumour weight (g) vs.
immune cells subset percentage in tumours of wild-type and H4R-
KO mice
Correlations Wild-type mice H4R-KO mice
Control Histamine Control Histamine
% NK cells N: 22 N: 16 N: 14 N: 10
P: ns P: ns P: ns P= 0.0544
r= –0.6364
% CD8+ T cells N: 33 N: 21 N: 17 N: 10
P: ns P: ns P: ns P= 0.0126
r= –0.7697
% CD8+ CD44+ T cells N: 10 N: 11 N: 10 N: 9
P: ns P: ns P: ns P= 0.0589
r= –0.6667
CD4+/CD8+ T cells N: 31 N: 21 N: 17 N: 10
P= 0.0069 P: ns P: ns P= 0.0037
r= 0.4752 r= 0.8424
Tumour cell suspensions from control and histamine- (5 mg kg−1) treated
mice were labelled with specific antibodies: CD49-PE and CD3-FITC: NK
markers, CD8-PE: cytotoxic T lymphocyte marker and CD44-FITC: lympho-
cyte activation marker. The percentage of each subset and the CD4+/CD8+
T lymphocyte ratio was correlated with tumour weight. Spearman
correlation coefficient (r) was calculated for each experimental group
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Fig. 4 Tumour growth parameters of 4T1 tumour-bearing mice treated with H4R ligands. 4T1 tumour-bearing mice were left untreated
(control) or were treated with 1 mg kg−1 of the H4R agonist JNJ28610244 (JNJ28) or 10 mg kg−1 of the H4R antagonist JNJ7777120 (JNJ77) for
15 days. a Tumour weight at the end of the experimental period (n= 12 control; n= 14 JNJ28; n= 9 JNJ77). Inset: Tumour growth curves show
the relative tumour volume for control and JNJ28-treated mice. b Spleen weight of control (n= 12), JNJ28 (n= 14) and JNJ77-treated (n= 9)
4T1 tumour-bearing mice. c The percentage of tumour-infiltrating lymphocytes (% TILs), determined by flow cytometric analysis of forward
vs. side scatter, was correlated with tumour weight for control (n= 10) and JNJ28-treated (n= 10) mice. Spearman correlation (P > 0.05).
d–k Tumour and tumour-draining lymph node (TDLN) cell suspensions were labelled with specific antibodies: d, g CD4-FITC: T helper
lymphocyte marker (n= 7 control; n= 9 JNJ28; n= 7 JNJ77 for intratumoural. n= 13 control; n= 15 JNJ28; n= 10 JNJ77 for TDLN), e, i CD8-PE:
T cytotoxic lymphocyte marker (n= 13 control; n= 15 JNJ28; n= 8 JNJ77 for intratumoural. n= 10 control; n= 11 JNJ28; n= 8 JNJ77 for
TDLN), f CD49-PE and CD3-FITC: NK markers (n= 8 control; n= 10 JNJ28; n= 4 JNJ77 for intratumoural). h CD4-FITC, CD25-APC and FoxP3-
FITC: regulatory T cells (n= 9 control; n= 11 JNJ28; n= 8 JNJ77 for TDLN). Box plots represent the median and interquartile range for each
experimental group (Kruskal–Wallis test, *P < 0.05). Spearman correlation of j the percentage of tumour-infiltrating immune cell subsets vs.
tumour weight and k the percentage of immune cell subsets in TDLN vs. tumour weight for mice treated with JNJ28 and JNJ77
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immune system in the response to anticancer treatments could
not be evaluated, the treatment with H4R agonists showed very
promising outcomes.18–21,40,53,54 In line with this, the results
indicate that elevated HRH4 gene expression was associated with
improved relapse-free survival outcomes in all breast cancer
patients.
The higher antitumoural and antimetastatic effects of histamine
treatment compared with JNJ28 administration could be asso-
ciated with the multifaceted action of histamine on different
receptors and cell types, which on the one hand balanced
antitumour immunity and on the other hand, by acting directly
through the H4R on 4T1 tumour cells, reduced proliferation.
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Fig. 5 Effect of histamine and H4R agonists on in vitro 4T1 cell growth. a Cells were left untreated (control) or were treated with histamine
(0.01–50 μmol L−1) or JNJ28 (JNJ28) (0.01–50 μmol L−1) for 7 days. Proliferation was evaluated by the clonogenic assay. The half-maximal
inhibitory concentration (IC50) is indicated for histamine and JNJ28. b Cells were treated with histamine (10 μmol L−1), JNJ28 (10 μmol L−1)
and/or JNJ77 (10 μmol L−1) for 7 days. Proliferation was evaluated by the clonogenic assay. c–h Cells were left untreated (control) or were
treated with 10 μmol L−1 of histamine, JNJ28 or VUF8430 for 48 h. c The cell viability was evaluated by Cell Titer Blue Assay. d BrdU
incorporation assay. e Percentage of TUNEL-positive cells. f Percentage of Annexin-V positive cells. g Measurement of mitochondrial
transmembrane potential by TMRE staining. CCCP (carbonyl cyanide m-chlorophenyl hydrazone), a mitochondrial oxidative phosphorylation
uncoupler, was used as a positive control. h Cytokine concentrations in 4T1 cells-conditioned medium. Error bars represent the mean ± SEM
(n= 3–5 independent experiments). (*P < 0.05, ANOVA and Newman–Keuls multiple comparison test)
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However, the precise mechanism underlying these effects
deserves further investigation.
These results highlight the complexity of cancer disease and the
critical interplay between tumour cells and host immune response
that determines the clinical therapeutic outcomes.
Based on the presented evidence, combining patients’ survival
analysis and in vitro and in vivo studies in TNBC model, we
conclude that HDC may be a potential prognostic biomarker in
breast cancer that could complement routine histopathological
analysis. Histamine is a promising drug to be used as a single or
combination therapy for TNBC treatment, which deserves to be
tested in prospective clinical trials. The fact that histamine has
already been approved to be used in humans reduces the gap
between experimental work and the potential clinical application.
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